U.S. v. GSK
In the largest health care fraud s ettlement in history, U.K. drugmaker GlaxoSmithKline plc agreed to pay a total of $3 billion in penalties to the U.S. government on July 2. The company pleaded guilty to criminal allegations that it had illegally promoted two drugs, Paxil and Wellbutrin, for “off-label” uses and failed to report safety data on a third, Avandia. For those charges, it paid nearly $1 billion in criminal fines. The company also agreed to pay $2 billion to settle civil allegations that it reported false “best prices” to the government; made misleading statements about Avandia’s safety; and promoted seven other drugs for unapproved uses. GSK did not admit to any wrongdoing in connection with the civil claims.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
